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Abstract Our purpose was to analyze the pattern of
failure in glioblastoma (GBM) patients at first recurrence
after radiotherapy and temozolomide and its relationship
with different factors. From 77 consecutive GBM patients
treated at our institution with fluorescence guided surgery
and standard radiochemotherapy, 58 first recurrences were
identified and included in a retrospective review. Clinical
data including age, Karnofsky performance score, preop-
erative tumor volume and location, extend of resection,
MGMT promoter methylation status, time to progression
(PFS), overall survival (OS) and adjuvant therapies were
reviewed for every patient. Recurrent tumor location
respect the original lesion was the end point of the study.
The recurrence pattern was local only in 65.5 % of patients
and non-local in 34.5 %. The univariate and multivariate
analysis showed that greater preoperative tumor volume in
T1 gadolinium enhanced sequences, was the only variable
with statistical signification (p \ 0.001) for increased rate
of non-local recurrences, although patients with MGMT
methylation and complete resection of enhancing tumor
presented non-local recurrences more frequently. PFS was
longer in patients with non-local recurrences (13.8 vs.
6.4 months; p = 0.019, log-rank). However, OS was not
significantly different in both groups (24.0 non-local vs.
19.3 local; p = 0.9). Rate of non-local recurrences in our
series of patients treated with fluorescence guided surgery
and standard radiochemotherapy was higher than previ-
ously published in GBM, especially in patients with longer
PFS. Greater preoperative enhancing tumor volume was
associated with increased rate of non-local recurrences.
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Introduction
Glioblastoma (GBM) is the most frequent malignant pri-
mary brain tumor in adults. Despite recent advances on
treatment the prognosis of GBM patients is still dismal,
with overall survival (OS) less than 10 % at 5 years [1].
Although autopsy studies suggest that GBM is diffusely
disseminated within the brain most of the recurrences occur
locally, i.e. at the primary site of the contrast enhancing
lesion. Thus, rates of local recurrence of 80–100 % are
widely accepted [2, 3].
The standard of care for GBM has changed during the
past decade with the addition of concomitant and adjuvant
chemotherapy with temozolomide (TMZ) to radiotherapy
[4] Also surgical approach has changed, with both fluo-
rescence guided surgery (FGS) with 5-aminolevulinic acid
(ALA) [5–7], and intraoperative magnetic resonance
imaging (MRI) [8, 9] leading to rates of complete resection
of the enhancing tumor (CRET) much greater than previ-
ously reported [10].
Most groups that have reviewed the issue in the present
decade agree that the addition of TMZ or more aggressive
local treatment have not changed the predominately local
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pattern of recurrence, [11–15]. However, other groups have
suggested that MGMT promoter methylation [16, 17],
CRET [18, 19], intensified local radiotherapy [20] and
tumor involvement of the subventricular zone (SVZ) are
related with higher rates of distant failure [21].
The relationship between the recurrence location and
survival is also complex. While some authors suggest that
distant failure is associated with worst overall survival
(OS) [22], others have found distant recurrences to be more
frequent in cases with longer OS [16].
We retrospectively reviewed our recent series of newly-
diagnosed GBM patients treated with 5-ALA guided sur-
gery, and standard radio-chemotherapy with temozolo-
mide, in order to analyse the recurrence pattern and its
relationship with different factors.
Materials and methods
From August 2007, we developed a prospective database
on the use of FGS. All patients had given informed consent
in accord with the Helsinki convention norms.
From this database, we identified 77 consecutive
patients with newly-diagnosed GBM resected. We retro-
spectively reviewed the pattern of first recurrence after the
initial surgery.
The standard management of these patients in our
Center had been as follow:
FGS was performed after oral administration of 20 mg/kg
of 5-ALA (Gliolan, Medac, Wedel, Germany) 2 h before
induction of anesthesia, as published [23]. A Pentero
microscope (Zeiss, Oberkochen, Germany) was used for
tumor resection. Volumetric measurement of the tumor
volume on T1Gd and T2, specific lobe involvement and
eloquent area involvement were analyzed upon preopera-
tive MRI. Tumor volume was measured with manual seg-
mentation using the iplan cranial software (BrainLab). The
target of the surgery was the resection of all the fluorescent
tissue in the surgery field when it was deemed safe.
Neurophysiological monitoring was used for tumors near
eloquent areas. When total removal of the fluorescence
tissue was not possible, based on monitoring data, it was
registered in the surgical sheet. All histological diagnoses
were established according to the WHO criteria. MRI
images were always obtained within the first 72 h after
surgery. Extent of resection (EOR) was calculated as per-
centage of (preoperative tumor volume-postoperative
tumor volume)/preoperative tumor volume [24]. CRET
was defined as the absence of contrast enhancement in the
volumetric analysis over the T1Gd on postoperative MRI
[25]. Follow-up MRIs were done before and after radio-
therapy and later every 2–3 months or when the patients
experienced neurological deterioration.
Clinical data including age and Karnofsky Performance
Score (KPS), and MGMT promoter methylation status as
determined by semi-quantitative PCR, were recorded pro-
spectively for every patient. All patients had received
standard radio-chemotherapy with temozolomide accord-
ing to the ‘‘Stupp’’ protocol. Thirty-six cases had also been
included in a phase II trial that added autologous dendritic
cells vaccination to the standard therapy (EudraCT:
2009-009879-35). After first relapse patients had been
treated at the criteria of their neurooncologist, including
reoperation and reirradiation if possible, and second-line
chemotherapy. The most common salvage therapy con-
sisted on bevazucimab.
For the retrospective review, recurrence was defined
according to RANO criteria [26]. Recurrence was classified
as local if it was located in the resection cavity or in con-
tinuity with it, or less than 2 cm from the primary tumor
margins and distant when the recurrence lesion border was
more than 2 cm from the previous cavity. For the statistical
analysis, the cases were distant and local recurrences
appeared at the same time were counted together with the
cases with distant only lesion and this group was called non-
local. Previous MRI were reviewed to look for abnormal
signal in T1Gd or T2 in the area of distant recurrence.
The recurrence location, progression free survival (PFS)
and OS data were obtained from the clinical registry in our
center. The patients with missing data were contacted by
phone if possible.
Statistical methods
Age and preoperative tumor volume were analyzed as
continue variables.
Location of the tumor and recurrences, KPS, MGMT
promoter methylation status and CRET were defined as
categorical variables.
PFS and OS were analyzed with Kaplan–Meier method;
comparisons were made using Log-rank test.
Chi square, t-Student tests and Mann–Whitney were
used for comparisons in the univariant models, as
appropriate.
Multivariate analysis with a logistic regression model
was used to assess relationship of age, KPS, MGMT
methylation status, CRET, and preoperative volume on
recurrence location.
Values with p \ 0.05 in these analyses were considered
statistically significant.
Results
Out of the 77 patients with first resection for a GBM, 58
have had a documented progression, 10 are alive without
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recurrence and 9 have died without known progression or
we did not had the MRI. Only the 58 patients with docu-
mented progression have been included in the analysis.
In 38 out of the 58 patients with a documented pro-
gression (65.5 % of the recurrent cases) the recurrent lesion
was local, in 16 (27.6 %) was distant, and in 4 cases there
were local and distant recurrences at the same time
(6.9 %). For comparisons, 34.5 % were classified as non-
local progressions, and 65.5 % were only local.
Clinical data of the patients are summarized in Table 1.
CRET was achieved in 44 out of 58 patients; mean EOR
in the whole series was 99.27 %. In the 14 cases with some
residual enhancing tumor volume, the mean residual
enhancing volume was 1.9 cc and the mean EOR was
96.8 %. The proportion of patients with non-local recur-
rence was greater for cases with CRET (41 vs. 21 %),
although the difference did not reach statistical significance
(p = 0.15, chi-test).
Total resection of fluorescence tissue was achieved in
77 %, and non-local recurrence was greater when all the
fluorescence tissue was removed (36.4 vs. 23.1 %), the
difference is not statistically significant (p = 0.37, chi-
test).
MGMT promoter status could not be determined in
8.6 % of the patients (5/58). In the remainder, it was found
to be methylated in 42 % and unmethylated in 58 %. The
proportion of patients with non-local recurrence was
greater for cases with methylated MGMT promoter (41 vs.
32 %), although the difference did not reach statistical
significance (p = 0.35, chi-test).
Mean preoperative tumor volume measured upon T1Gd
was 36.8 cc for patients with local recurrence and 49.9 cc
for patients with non-local recurrence (p \ 0.001 t test).
Subgroup analysis showed the difference to be due to the
fourth quartile: patients with preoperative tumor volumes
higher than 54 cc had a 66.6 % rate of non-local recur-
rence, while the patients within the first, second and third
quartiles had rates of 41, 33, and 7 %, respectively.
Mean preoperative volume of the abnormal area in T2
was 87.24 cc. It was 92.73 cc in patients with local
recurrence, and 81.75 cc in patients with non-local recur-
rence (p = 0.933).
No signal abnormalities were observed in the area where
the distant recurrence later occurred in any case.
Recurrence was non-local in 33.3 % of the patients
included in immunotherapy protocol and in 39 % of the
patients not included (p = 0.42).
Tumor involving the SVZ was analysed following the
classification published before [21], however, in our series
a relationship was not found between tumor location and
location of recurrence (p = 0.6) (Fig. 1).
In the multivariate analysis, the preoperative tumor
volume was statistically significant (p = 0.014), and CRET
was near significance in some models. Both CRET and
MGMT promoter had high HR that could suggest influ-
ence, albeit they did not reach significance, perhaps due to
the small sample size. Table 2 shows the model with
CRET, methylation of MGMT promoter, and preoperative
volume. The statistical significance did not change in
models where we excluded patients with local and distant
recurrence from the analysis (data not shown).
Median PFS was significantly longer for patients with
non-local recurrences than for patients with local recur-
rences (13.8 vs. 6.4 months; p = 0.019, log-rank).
Although OS was different in both groups (24.0 non-
local vs. 19.3 local; p = 0.9), the difference was not sig-
nificant, perhaps due to small sample size.
Survival since progression was significantly shorter for
patients with non-local progression than for patients with
local progression (7.5 vs. 12.0 months, p = 0.017) (Fig. 2).
Median overall survival of the whole series was
21.2 months.
Discussion
Non-local recurrence after treatment for glioblastoma have
been historically considered very rare. Many authors have
reviewed this issue in recent years, after the introduction of
radiotherapy and temozolomide as standard, and most of
them state that it has not changed, with rates of distant
Table 1 Clinical data of patients progressed
Local
recurrence
Non- local
recurrence
p value
Mean age 59 58 0.312
T1-Gd preoperative
volume
36.7 cc 49.9 cc \0.001*
T2-FLAIR
preoperative volume
92.73 cc 81.75 cc 0.933
Karnofsky
70–100 72 % 28 % 0.175
\70 54 % 46 %
MGMT
Methylated 59 % 41 % 0.107
Non-methylated 68 % 32 %
Extend of resection
CRET 59 % 41 % 0.412
No CRET 79 % 21 %
Included in vaccine
trial
46 % 52 % 0.307
Median PFS 6.4 13.8 0.019*
Median OS 19.3 24 0.9
CRET complete resection of enhanced tumor, PFS progression free
survival, OS overall survival
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lesions at first recurrence between 2 and 28 %, mostly
below 20 % [12–17, 19, 27–30]. However, it has been
suggested that some factors increase the rate of distant
recurrence only in certain subgroups, such as patients with
methylated MGMT promoter [16, 17], very extensive
resections [18, 19], and tumor involvement of the sub-
ventricular zone (SVZ) [21].
We found a rate of distant first recurrence higher than
previous papers. Making comparisons can be difficult, as
the patterns of relapse are not universally defined, and
different classifications are employed. Usually, the classi-
fication used is based on the specific factors being studied.
Radiotherapy studies mostly define recurrences in three
groups related to the radiation field [12, 16, 27, 28, 30].
Surgery based studies use the distance to the resection
cavity [14, 18]. Pope et al. [11, 29] proposed a classifica-
tion considering both the place and the aspect of the
recurrence that have been applied in recent studies of
antiangiogenic drugs. Despite the different classifications,
two simple groups can be identified in all studies: local
recurrence and non-local recurrence. We believe that these
two groups summarise the disease behaviour in a simple
scheme, making possible to compare results published in
the literature. In our series, we found 27.6 % distant only,
and 6.9 % distant and local at the same time. The
appearance of distant disease marks an important stage in
the GBM evolution, with different treatment needs, so the
grouping as non-local of all cases with any distant disease
makes clinical sense. It is also an easy data to compare
between groups. Both the 27.6 % distant only and the
Fig. 1 63 years-old female with GBM. MRI at diagnosis (upper row)
and first recurrence (lower row). At diagnosis a left parieto-occipital
mass was found, hyperintense in T2 FLAIR (arrow in a) and with
irregular peripheral enhancement with central necrosis in T1Gd
(arrow in b), with normal left temporal lobe (c and d). 13 months
after surgery there was no evidence of recurrence at the surgical
cavity borders with only treatment-related changes, with gliosis in T2
FLAIR (arrow in e) and a small stable area on enhancement in T1
Gad (arrow in f). Yet a new remote nodule appeared in the left
temporal lobe, outside the radiation field (arrows in g and h),
confirmed to be a GBM recurrence after surgery
Table 2 Multivariate analysis including complete resection of
enhanced tumor (CRET), fluorescence tissue resection (Fl. Tissue
resection), preoperative volume, MEGMT methylation status, age and
Karnovsky Performance Score (KPS)
B E.T. Wald gl Sig. Exp
(B)
CRET 2.242 1.283 2.743 3.055 1 0.08
Fl. tissue resection 1.366 0.837 2.663 1 0.103 3.92
Preoperative
volume
0.032 0.016 3.968 1 0.046 1.033
MGMT-met 1.367 0.797 2.946 1 0.086 3.925
Age -0.014 0.034 0.158 1 0.691 0.986
KPS 0.033 0.031 1.139 1 0.286 1.034
Bold value indicates statistically significant
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34.5 % non-local are higher than data published before.
Table 3 presents the results from the papers that disclose
data of the first recurrence in patients who have been
treated with the actual standard therapeutic protocol.
We analysed our data looking for the factors behind this
high rate of non-local first recurrence.
The clinical characteristics of the patients included in
the series, based on age and functional status were quite
normal and had no correlation to the pattern of recurrence.
MGMT promoter methylation is well recognized as a
favourable prognosis factor in GBM and two papers have
already reported that the pattern of recurrence can be sig-
nificantly influenced by it [16, 17]. In these two papers, rate
of non-local failure was greater for patients with methyl-
ated MGMT promoter, with 42 versus 15 % [16] and
21–8 % [17]. This difference was also present in our series
(41 vs 28 %) although the unmethylated group had also a
high rate of non-local recurrence, which coupled with the
small number of patients, prevented the difference from
reaching statistical significance.
The main selection bias of our series is that all the cases
were candidates to resection surgery and had extensive
removal, even the subgroup with some residual tumor had a
mean tumor volume of 1.9 cc. In this regard, is important
to point out that the criteria for surgical resection in our
department are wide, we exclude for surgery only patients
with diffuse invasion of eloquent areas, and most of the
patients treated in our institution receive resection surgery.
The intention to do maximal resection is standard in our
department, and we have previously shown that the routine
use of FGS provides a high rate of CRET and very high
mean EOR [6]. Two recent series have focused in the
pattern of recurrence in patients with CRET followed by
radiotherapy plus temozolomide. Petrecca found only 15 %
of non-local recurrences after complete tumor resection
and standard treatment with radiotherapy and temozolo-
mide[14]. De Bonis published their data on recurrences
after CRET in a very selected population where non-elo-
quent locations allowed an en bloc resection. This group
studied two subsets of patients: one with resection limited
to the tumor border (BR) visible in the surgical piece exam
and one with extended resection (ER), with more than 1 cm
beyond the tumor border. They found a higher than
expected rate of non-local recurrences, 33 %, only in the
group with ER, with BR having 12.5 %. Our whole series
has a percentage of non-local recurrent similar to the group
of ER in De Bonis series.
The most likely explanation for the high rate of non-
local recurrence is the more extensive resection associated
to FGS. The association between greater resection and non-
local recurrences has appeared in some previous works
only for the most extensive resections. In the present data
the rate of non-local relapse is higher for the whole series
because FGS guided resections can be more extensive that
the resection of the tissue visible in T1Gd MRI. Previous
data have shown that the fluorescence induced by 5-ALA
show more tumor than the T1Gd sequence [23] [31]. We
found than patients with resection deemed complete by
both MRI and fluorescent light live longer than those
patients with resection complete only by MRI [32]. The
tendency of GBM to quick local regrowth is highlighted by
reports showing local progression before radiotherapy in 53
[33] and 38 % [34] of patients, probably the elimination of
a greater amount of invasive cells around the core of the
tumor helps to achieve local control, but do not stop the
disease.
We found an influence of preoperative volume that has
not been described previously, but offered a robust
Fig. 2 Kaplan–Meier curves for progression free survival (PFS) and overall survival (OS)
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statistical significance. We added a multivariate analysis
that has not been done in previous papers, including all the
variables with possible relevance. This model confirms the
significance of preoperative tumor volume, and shows
CRET as almost significant. We can speculate that the
infiltrated brain volume around a big tumor is much bigger
than in a smaller tumor due to the exponential relationship
between volume and radius.
Treatment after surgery included radiotherapy plus
temozolomide as intention to treat in all the patients. The
group of patients which received immunotherapy added to
the standard had a slightly lower rate of non-local recur-
rence, so this experimental therapy cannot explain the high
rate of non-local recurrence observed, albeit it may have an
impact in the OS of the total series.
Lim et al. [21] found an association between distant
recurrences and tumor relationship to subventricular zone
(SVZ), concluding that those tumors in contact with the
SVZ were more likely to have distant recurrences than
tumors not involving the SVZ. We did not find this rela-
tionship in our series.
PFS was longer in patients with non local recurrences,
as reported by other authors [16, 17]. Despite this associ-
ation, OS difference was small and not reached statistical
significance (24.0 non-local vs. 19.3). The better PFS was
counterbalanced by a much shorter survival from the time
of progression in distant recurrence patients. We believe
this paradox indicates how the disease advances. Multi-
centricity has been associated with poor prognostic in
GBM. In the multivariate analysis of the radiographic
characteristics made by Pope, multicentricity had the worst
OS [22]. The patients with better surgery get more local
control and longer PFS but, once a distant lesion appears,
the disease has progressed and they have the same short
survival from that moment of the initially multicentric, as
have been nicely showed previously by Hefti [35].
The PFS and OS data suggest that a very extensive
resection can increase the local control, however, the sur-
gery has no effect over distant cells and the cells that
infiltrate distally reproduce the tumor. It seems that this
cells situated farther and being at low density, need more
time to produce a visible recurrence, albeit once the tumor
distant recurrence appears, it signals more advanced dis-
ease and the remaining survival time is short.
The OS in our series is longer than most series of GBM
cases, probably reflecting the combined effect of extended
resection with FGS, radiotherapy, temozolomide, plus
second line therapies and plus immunotherapy in almost
half the patients. Our data suggests than improvement of OS
through local control will lead to more distant failure cases,
unless we found a therapy to effectively tackle the invasion.
Conclusions
Our results suggest that improvement in surgical treatment
of GBM with FGS added to standard therapy can influence
the pattern of relapse, increasing distant recurrences in
patients with longer PFS. Greater preoperative enhancing
tumor volume is associated with increased rate of non-local
recurrences. Novel therapies should be directed to diffuse
invasive disease in the brain to be effective.
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